Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More General business news Cyient DLM announces stellar financial performance for FY24 with PAT increase of 93% Cyient DLM, a leader in design-led manufacturing, has reported its financial results for the fourth quarter ending March… byPallavi MadhirajuApril 24, 2024